Sophie Andrieu-Key

We don’t have enough information about this author to calculate their statistics. If you think this is an error let us know.
Learn More
context of the patient's individual needs and preferences. Let's not expend any further stomach acid on this issue, agree that we all are ethical and capable physicians trying to bring the best solutions to our patients and continue to collaborate on meeting the real unmet needs of our patients. disclosure The authors have declared no conflicts of interest.(More)
ALK-rearrangements are mainly encountered in lung adenocarcinomas and allow treating patients with anti-ALK targeted therapy. ALK-rearranged squamous cell lung carcinomas are rare tumors that can also respond to anti-ALK-targeted therapy. Nevertheless, ALK screening is not always performed in patients with squamous cell lung carcinomas making the(More)
Searching for ALK rearrangements has now become mandatory for the treatment of patients with advanced non-small cell lung cancer with anti-ALK-targeted therapy. The fluorescence in situ hybridization test is considered the "gold standard" to diagnose ALK-rearranged tumors. Nevertheless, some technical pitfalls may cause false-positive signals mimicking ALK(More)
Searching for ALK rearrangements using the approved fluorescent in situ hybridization (FISH) test and complementary immunohistochemistry (IHC) has become the rule to treat patients with advanced non‑small cell lung cancer (NSCLC) with anti‑ALK targeted therapy. The concordance between the two techniques is reported to be strong but imperfect. We report our(More)
  • 1